Temporary Suspension

Akers Biosciences, Inc.

("ABI" or the "Company")

Temporary Suspension

Due to the Company's proposed public offering (the "Offering") and admission to trading on The NASDAQ Capital Market ("NASDAQ"), the Company is in the process of submitting an amendment to its registration statement with the SEC, which includes the pricing disclosure relating to the Offering. Until such time as that registration statement becomes effective, and trading commences on NASDAQ, the Company has requested a suspension in trading of its shares on AIM. A further announcement will be made in due course.

For more information:

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.